Supervisory board

Dr. Gerd Zettlmeissl

Dr. Gerd Zettlmeissl

Chairman of the Supervisory Board

Year of birth: 1955
Current place of residence: Vienna, Austria
Independent: Yes

Dr. Zettlmeissl has more than 30 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies.

Until early 2015 he was Chairman of the Supervisory Board of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline and until 2020 Chairman of Themis Bioscience (Austria), a vaccine/immunotherapy company acquired by Merck Shark Dhome. He is the former CEO of the Austrian-based biotechnology company Intercell (now Valneva). While at Intercell from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine and oversaw efforts to build and advance a broad-based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.

Dr. Zettlmeissl joined Medigene’s Supervisory Board in 2017 for the first time and is mandated until 2023. He holds the following essential positions besides the Supervisory Board Mandate:

  • Chairman of the Supervisory Board, MSD Wellcome Trust Hilleman Laboratories, New Delhi, India

As of 25 June 2021

Antoinette Hiebeler-Hasner

Antoinette Hiebeler-Hasner

Deputy Chair of the Supervisory Board

Year of birth: 1958
Current place of residence: Munich
Independent: Yes

Ms. Hiebeler-Hasner has started her career with Peat Marwick Mitchell & Co. now KPMG after having studied business administration at the Ludwig Maximilians University in Munich. As a tax consultant she founded her own tax consultancy firm in 1988. After various mergers with other consultancies the optegra consultancy group was established, with offices in Cologne and in Munich. Since October 2017, this company has been operating as Vistra Wirtschaftsprüfungsgesellschaft after the integration of the optegra Group into the globally active Vistra Group. Since October 2018, Ms. Hiebeler-Hasner has been Country Director for all Vistra companies in Germany. Furthermore, Ms. Hiebeler-Hasner and her brothers founded H3 Aerospace, which purchased Grob Aircraft in 2009. Grob Aircraft is a medium-sized company, with more than 250 employees, which develops and produces training aircrafts that are successfully sold world-wide. Apart from the professional abilities of Ms. Hiebeler-Hasner, which include proficiency with regard to financial statements, securing of accounting continuity and tax consultancy, Ms. Hiebeler-Hasner is also able to offer a huge entrepreneurial expertise due to her various business activities.

Ms. Hiebeler-Hasner joined Medigene’s Supervisory Board in 2016 for the first time and is mandated until 2022. She holds the following essential positions besides the Supervisory Board Mandate:

  • Chairperson of the Supervisory Board, Grob Aircraft SE, Tussenhausen-Mattsies, Germany
  • Member of the Supervisory Board, Ventuz Technology AG, Hamburg, Germany

As of 25 June 2021

Dr. Anthony Man

Dr. Anthony Man

Member of the Supervisory Board

Year of birth: 1956
Current place of residence: Allschwil, Switzerland
Independent: Yes

Dr. Anthony Man, since 2017 Global Clinical Development Head, Communicable Diseases, Global Health Development Unit at Novartis Pharma in Basel, Switzerland, is a medically qualified professional with over 30 years of international drug development experience in the pharmaceutical and biotechnology industry. This includes previous significant roles in the development and approval of around 30 different new drugs in multiple therapeutic areas (including oncology) and senior executive management responsibilities in companies such as Novartis and Roche, among others.

Dr. Man joined Medigene’s Supervisory Board in 2020 and is mandated until 2023. He does not hold essential positions besides the Supervisory Board mandate.

As of 25 June 2021

Dr. Keith Manchester

Dr. Keith Manchester

Member of the Supervisory Board

Year of birth: 1968
Current place of residence: New York, USA
Independent: Yes

Keith Manchester serves as a Partner and the Head of Life Sciences at QVT Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. He received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

Dr. Manchester joined Medigene’s Supervisory Board in 2017 for the first time and is mandated until 2022. He holds the following essential positions besides the Supervisory Board Mandate:

  • Director, Arbutus Biopharma Corporation, Canada (listed)
  • Director, Roivant Sciences, Inc., Delaware, USA and Roivant Sciences Ltd., Bermuda
  • Director, Kriya Therapeutics, Redwood City, USA

As of 25 June 2021

Dr. Frank Mathias

Dr. Frank Mathias

Member of the Supervisory Board

Year of birth: 1962
Current place of residence: Munich
Independent: Yes

Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 30 years’ experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst. After that, he became General Manager of renowned companies such as Servier Deutschland and Amgen Deutschland in Munich. Dr. Mathias was Chief Executive Officer of Medigene from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer responsible for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies.

Dr. Mathias joined Medigene’s Supervisory Board in 2018 for the first time and is mandated until 2022. He holds the following essential positions besides the Supervisory Board Mandate:

  • CEO of Rentschler SE, Laupheim, Germany
  • Chairperson of the Supervisory Board of Mediatum AG, Heidelberg, Germany

As of 25 June 2021

Ronald Scott

Ronald Scott

Member of the Supervisory Board

Year of birth: 1955
Current place of residence: Riehen, Switzerland
Independent: Yes

Ronald Scott served as Chief Executive Officer of Basilea Pharmaceutical International from January 2013 until April 2018. He was Basilea's Chief Operating Officer from January through December 2012, and served as Basilea's Chief Financial Officer from the Company’s founding in 2000 through January 2012 as well as ad interim Chief Financial Officer from February 2013 until November 2013. From 2004 to October 2011, Mr. Scott served on the Board of Directors and was a co-founding Board member in 2000.

Prior to joining Basilea, Mr. Scott worked at Roche Holding (Roche) in management positions in Pharmaceutical Finance, Licensing, and the Roche Corporate Finance Mergers and Acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as Director in Prudential’s Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a bachelor’s degree from Utah State University (USA) and a master’s degree from Harvard University (USA).

Mr. Scott joined Medigene’s Supervisory Board in 2017 for the first time and is mandated until 2023. He is independent and holds the following essential positions besides the Supervisory Board Mandate:

  • Member of the Board of Directors (Verwaltungsrat), Basilea Pharmaceutical International Ltd., Basel, Switzerland

As of 25 June 2021